CEO's Defending and Pledging to Bring the Company Up
Hong Kong-based Regencell Bioscience is an early clinical stage bioscience company, founded in 2014, is in the business of using traditional Chinese medicine (”TCM”) approach to develop standardized TCM formulas to holistically treat autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in children, and infectious diseases which affects the immune system such as COVID-19.
The company’s formula aims to treat the core causes of disorders while reducing the symptoms and improving overall health of its patients at the same time. The direction of using natural ingredients (herbs) to treat elements in the body is taken as the company’s holistic approach toward the treatment process while preparing the TCM formulae for its patients.
In order to approach the public with a transparent front, RGC’s CEO has decided to take a more approachable and honest form that is to well-align with shareholder’s long-term interests.
Taken from the CEO’s schedule 13D fillings with the SEC (US Security and Exchange Commission), the CEO has used an estimated amount of 5 million dollars of his personal funds to purchase ordinary shares via open market between July 21 and May 22’. This sums up a total of 10,539,159 ordinary shares owned by the CEO (Mr Au); representing ~81% of the company’s total issued and outstanding shares.
To gain further trust of fellow investors, Mr Au has pledge with the following points,
- Pledged to not draw salary and bonus of more than USD $1 until the Company reaches USD $1 billion market capitalization;
- Will not award share options for himself;
- All directors and employees who were previously granted stock options upon the Company’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
[https://finance.yahoo.com/news/rgc-ceo-figuratively-putting-money-092700965.html]
Mr Au is also been involved in his own philanthropic project (within his own means) and aims to provided care to over 10,000 affected children with ADHD, ASD and Covid-19 and also those affected by financial difficulties. As of today, Mr Au’s project has personally helped over 150 children since the launch of this project on April 16, 22.
Hong Kong-based Regencell Bioscience is an early clinical stage bioscience company, founded in 2014, is in the business of using traditional Chinese medicine (”TCM”) approach to develop standardized TCM formulas to holistically treat autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in children, and infectious diseases which affects the immune system such as COVID-19.
The company’s formula aims to treat the core causes of disorders while reducing the symptoms and improving overall health of its patients at the same time. The direction of using natural ingredients (herbs) to treat elements in the body is taken as the company’s holistic approach toward the treatment process while preparing the TCM formulae for its patients.
In order to approach the public with a transparent front, RGC’s CEO has decided to take a more approachable and honest form that is to well-align with shareholder’s long-term interests.
Taken from the CEO’s schedule 13D fillings with the SEC (US Security and Exchange Commission), the CEO has used an estimated amount of 5 million dollars of his personal funds to purchase ordinary shares via open market between July 21 and May 22’. This sums up a total of 10,539,159 ordinary shares owned by the CEO (Mr Au); representing ~81% of the company’s total issued and outstanding shares.
To gain further trust of fellow investors, Mr Au has pledge with the following points,
- Pledged to not draw salary and bonus of more than USD $1 until the Company reaches USD $1 billion market capitalization;
- Will not award share options for himself;
- All directors and employees who were previously granted stock options upon the Company’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
[https://finance.yahoo.com/news/rgc-ceo-figuratively-putting-money-092700965.html]
Mr Au is also been involved in his own philanthropic project (within his own means) and aims to provided care to over 10,000 affected children with ADHD, ASD and Covid-19 and also those affected by financial difficulties. As of today, Mr Au’s project has personally helped over 150 children since the launch of this project on April 16, 22.
